Six-hour trimethoprim-sulfamethoxazole-graded challenge in HIV-infected patients. 1998

P Demoly, and D Messaad, and H Sahla, and J Fabre, and V Faucherre, and P André, and J Reynes, and P Godard, and J Bousquet
Maladies Respiratoires, Hôpital Arnaud de Villeneuve, Montpellier; Maladies Infectieuses et Tropicales, Hôpital Guy de Chauliac, Montpellier, France.

BACKGROUND Hypersensitivity reactions to trimethoprim-sulfamethoxazole (TMP-SMX) are very common in HIV-infected patients, leading to drug discontinuation. However, it is the drug of choice as prophylaxis for Pneumocystis carinii pneumonia. OBJECTIVE We sought to determine the safety and long-term efficacy of a 6-hour TMP-SMX-graded challenge in a group of hypersensitive HIV-infected patients. METHODS Forty-four consecutive HIV-infected patients with documented TMP-SMX hypersensitivity were seen in our outpatient allergy department. They ingested 12 doses of increasing amounts of TMP-SMX at half-hour intervals. Thereafter, they took 80/400 mg TMP-SMX daily and were advised to "treat through" every nonbullous cutaneous adverse reaction. RESULTS All 44 patients tolerated the procedure without any adverse reactions during the day of challenge. Eleven of the 44 patients experienced mild hypersensitivity reactions on days 1 to 2 (8 patients) and 8 to 10 (3 patients), consisting mainly on a 1-day pruritic maculopapular eruption. Two patients stopped TMP-SMX at day 1, and 2 stopped it at days 10 and 15, giving an overall success rate at 1 month of 91% (40 of 44). Two were successfully rechallenged late. After a median follow-up of 10 months, 42 patients were taking TMP-SMX without any adverse reaction, giving an overall success rate of 95%. CONCLUSIONS A 6-hour graded challenge with cautious "treating through" of mild reactions enables more patients to take TMP-SMX and is safe and effective.

UI MeSH Term Description Entries
D008297 Male Males
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004342 Drug Hypersensitivity Immunologically mediated adverse reactions to medicinal substances used legally or illegally. Allergy, Drug,Hypersensitivity, Drug,Drug Allergy,Allergies, Drug,Drug Allergies,Drug Hypersensitivities,Hypersensitivities, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D015662 Trimethoprim, Sulfamethoxazole Drug Combination A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS. Trimethoprim-Sulfamethoxazole Combination,Abactrim,Bactifor,Bactrim,Biseptol,Biseptol-480,Centran,Centrin,Co-Trimoxazole,Cotrimoxazole,Drylin,Eslectin,Eusaprim,Insozalin,Kepinol,Kepinol Forte,Lescot,Metomide,Oriprim,Septra,Septrin,Sulfamethoxazole-Trimethoprim Combination,Sulprim,Sumetrolim,TMP SMX,TMP-SMX,Trimedin,Trimethoprim-Sulfamethoxazole,Trimethoprimsulfa,Trimezole,Trimosulfa,Biseptol 480,Biseptol480,Co Trimoxazole,Sulfamethoxazole Trimethoprim Combination,Trimethoprim Sulfamethoxazole,Trimethoprim Sulfamethoxazole Combination

Related Publications

P Demoly, and D Messaad, and H Sahla, and J Fabre, and V Faucherre, and P André, and J Reynes, and P Godard, and J Bousquet
June 1994, The Journal of allergy and clinical immunology,
P Demoly, and D Messaad, and H Sahla, and J Fabre, and V Faucherre, and P André, and J Reynes, and P Godard, and J Bousquet
February 1998, The Annals of pharmacotherapy,
P Demoly, and D Messaad, and H Sahla, and J Fabre, and V Faucherre, and P André, and J Reynes, and P Godard, and J Bousquet
April 2015, AIDS (London, England),
P Demoly, and D Messaad, and H Sahla, and J Fabre, and V Faucherre, and P André, and J Reynes, and P Godard, and J Bousquet
June 1995, AIDS (London, England),
P Demoly, and D Messaad, and H Sahla, and J Fabre, and V Faucherre, and P André, and J Reynes, and P Godard, and J Bousquet
June 2004, Mayo Clinic proceedings,
P Demoly, and D Messaad, and H Sahla, and J Fabre, and V Faucherre, and P André, and J Reynes, and P Godard, and J Bousquet
September 2020, The Annals of pharmacotherapy,
P Demoly, and D Messaad, and H Sahla, and J Fabre, and V Faucherre, and P André, and J Reynes, and P Godard, and J Bousquet
June 1999, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
P Demoly, and D Messaad, and H Sahla, and J Fabre, and V Faucherre, and P André, and J Reynes, and P Godard, and J Bousquet
January 1998, Pharmacotherapy,
P Demoly, and D Messaad, and H Sahla, and J Fabre, and V Faucherre, and P André, and J Reynes, and P Godard, and J Bousquet
June 1997, Pediatric emergency care,
P Demoly, and D Messaad, and H Sahla, and J Fabre, and V Faucherre, and P André, and J Reynes, and P Godard, and J Bousquet
January 2012, Indian journal of pharmacology,
Copied contents to your clipboard!